ArticleBMC biotechnology2013
Simultaneous display of two large proteins on the head and tail of bacteriophage lambda.
Article in BMC biotechnology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 24 citations in OpenAlex.
- Article
- A virus based vaccine combined with IL12 gene therapy eradicates aggressive melanoma.Scientific reports · 2025Article
- A Lambda-evo (λApplied microbiology and biotechnology · 2025Article
- EngineeredFrontiers in microbiology · 2025Article
- Phage-based delivery systems: engineering, applications, and challenges in nanomedicines.Journal of nanobiotechnology · 2024Review
- An Engineered M13 Filamentous Nanoparticle as an Antigen Carrier for a Malignant Melanoma Immunotherapeutic Strategy.Viruses · 2024Article
- Engineered phage with cell-penetrating peptides for intracellular bacterial infections.mSystems · 2023Article
- Review
- Control of λ LysogenicACS synthetic biology · 2022Article
- Apoptosis like symptoms associated with abortive infection of Mycobacterium smegmatis by mycobacteriophage D29.PloS one · 2022Article
- Phage engineering and the evolutionary arms race.Current opinion in biotechnology · 2021Review
- Review
- Single Domain Antibodies Targeting Receptor Binding Pockets of NadA Restrain Adhesion ofFrontiers in molecular biosciences · 2020Article
- Bacteriophages and phage-inspired nanocarriers for targeted delivery of therapeutic cargos.Advanced drug delivery reviews · 2016Review
- Construction of helper plasmid-mediated dual-display phage for autoantibody screening in serum.Applied microbiology and biotechnology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundConsistent progress in the development of bacteriophage lambda display platform as an alternative to filamentous phage display system was achieved in the recent years. The lambda phage has been engineered to display efficiently multiple copies of peptides or even large protein domains providing a powerful tool for screening libraries of peptides, proteins and cDNA.
resultsIn the present work we describe an original method for dual display of large proteins on the surface of lambda particles. An anti-CEA single-chain antibody fragment and green fluorescent protein or alkaline phosphatase were simultaneously displayed by engineering both gpD and gpV lambda proteins.
conclusionsHere we show that such modified phage particles can be used for the detection of target molecules in vitro and in vivo. Dual expression of functional moieties on the surface of the lambda phage might open the way to generation of a new class of diagnostic and therapeutic targeted nanoparticles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.